New White Paper: Proactive Planning to Optimize the Use of Biomarkers in Oncology Clinical Trials

Oncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized. Yet this good news comes with critical operational considerations that can mean the difference between success and failure.

This free white paper from Pat Devitt, President, Precision for Medicine Oncology and Rare Disease, will help you:

  • Pressure-test your approach to using biomarkers in clinical trials
  • Understand how peers are reducing approval times
  • Leverage new solutions to integrate, harmonize, and analyze multiomic data

Begin optimizing your biomarker strategy—download the white paper now.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics, adaptive clinical trial execution to regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.